# A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

> **NCT01609933** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 32 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** ABT-450/r
- **DRUG:** ABT-267
- **DRUG:** pegylated interferon alpha-2a (pegIFN)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01609933
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-18
- **Primary completion:** 2017-05-03
- **Final completion:** 2017-05-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609933, "A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01609933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*